The Role of CD90 in the Differential Diagnosis of Pleural Malignant Mesothelioma, Pulmonary Carcinoma and Comparison with Calretının
Authors:
- 19 October 2016
- journal article
- research article
- Published by Springer Nature in Pathology and Oncology Research
- Vol. 23 (3) , 487-491
Abstract
Pleural Malignant Mesothelioma (MM) is a fatal disease that has been associated with asbestos exposure. Differential diagnosis between the pleural infiltration of pulmonary carcinomas and MM is rather difficult particularly for epitheloid type mesothelioma.We aimed to investigate the utility of CD90, a cancer stem cell marker, in the differential diagnosis of MM and lung carcinoma, its prognostic significance and compare its value with that of Calretinin. Ninety pathology specimens including MM (n:30), pulmonary adenocarcinoma (n:30) and pulmonary squamous cell carcinoma (n:30) were used in this study. Immunohistochemical comparision of CD 90 and Calretinin was made in all groups. Calretinin was positive in 20 cases with MM (64.5 %), and was negative in 10 (32.3 %). CD 90 was positive in 25 of these cases (80 %) and negative in 5 (16 %). On the other hand pulmonary adenocarcinomas and squamous cell carcinomas showed positivity with CD90, 63,6 % and 73 %, respectively. We think that CD 90 has no place in the differential diagnosis between mesothelioma and pulmonary carcinoma because of the low specificity in spite of the high sensitivity.Keywords
This publication has 16 references indexed in Scilit:
- Claudin 3, 4, and 15 expression in solid tumors of lung adenocarcinoma versus malignant pleural mesotheliomaAnnals of Diagnostic Pathology, 2015
- Pathologic diagnosis of malignant mesothelioma: chronological prospect and advent of recommendations and guidelines2015
- Investigation of diagnostic utility and expression profiles of stem cell markers (CD133 and CD90) in hepatocellular carcinoma, small cell dysplasia, and cirrhosisPathology - Research and Practice, 2014
- Value of glut-1 and koc markers in the differential diagnosis of reactive mesothelial hyperplasia, malignant mesothelioma and pulmonary adenocarcinomaTurkish Journal of Pathology, 2013
- Identification of Novel Markers for the Diagnosis of Malignant Pleural MesotheliomaThe American Journal of Pathology, 2011
- Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?Pathology - Research and Practice, 2009
- Caveolin‐1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinomaHistopathology, 2009
- Caveolin‐1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastasesHistopathology, 2009
- Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificityLaboratory Investigation, 2006
- The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative studyLaboratory Investigation, 2006